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(57) ABSTRACT 
The invention involves a device and method for ascertaining 
the functioning of the respiratory system and determining 
whether a pulmonary embolism is present. The device 
comprises an apparatus containing sensors which measure 
the amount of a particular gas expired from a patient's lungs, 
including a non-ambient gas which is previously provided to 
the patent. From this data, a processor computes the con-
centration of expired gas as a function of expired volume 
and displays the results on a screen. By comparing the 
results to predetermined values from afflicted and healthy 
patient populations, an accurate determination can be made 
regarding the presence of a pulmonary embolism. 
9 Claims, 4 Drawing Sheets 
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NON-INVASIVE DEVICE AND METHOD FOR 
THE DIAGNOSIS OF PULMONARY 
VASCULAR OCCLUSIONS 
2 
min and therefore produced naturally whenever clots form in 
the body. As a result, the D-dimer assay is extremely 
sensitive for the presence of a pulmonary embolism but is 
very nonspecific. In other words, if the D-dimer assay is 
CROSS-REFERENCE TO PRIOR APPLICATION 
The present application is a continuation-in-part of U.S. 
patent application, Ser. No. 09/965,303 filed Sep. 27, 2001 
now U.S. Pat. No. 6,575,918. 
5 normal, the clinician has a reasonably high degree of cer-
tainty that no pulmonary embolism is present. However, 
many studies have shown a D-dimer assay is only normal in 
less than 1/3 of patients and thus produces a high degree of 
false positives. As a result, the D-dimer assay does not 
BACKGROUND OF THE INVENTION 
1. Field of Invention 
10 obviate formal pulmonary vascular imaging in most patients 
with symptoms of a pulmonary embolism. 
In an attempt to increase the accuracy of diagnostic, 
physicians have recently turned to methods which can 
produce an image of a potentially afflicted lung. One such 
The present invention relates generally to vascular occlu-
sions of the respiratory system, and more particularly to 
non-invasive devices and methods for the diagnosis of a 
pulmonary embolism and related disorders. 
2. Description of Prior Art 
15 method is a nuclear perfusion study which involves the 
injection of a small amount of radioactive particles into a 
vein. The radioactive particles then travel to the lungs where 
they highlight the perfusion of blood in the lung based upon 
whether they can penetrate a given area of the lung. While 
A pulmonary embolism occurs when an embolus become 
lodged in lung arteries, thus blocking blood flow to lung 
tissue. An embolus is usually a blood clot, known as a 
thrombus, but may also comprise fat, amniotic fluid, bone 
marrow, tumor fragments, or even air bubbles that block a 
blood vessel. Unless treated promptly, a pulmonary embo-
lism can be fatal. In the United States alone, around 600,000 
cases occur annually, 10 percent of which result in death. 25 
20 normal results can indicate that a patient lacks a pulmonary 
embolism, an abnormal scan does not necessarily mean that 
a pulmonary embolism is present. Nuclear perfusion is often 
performed in conjunction with a lung ventilation scan to 
The detection of a pulmonary embolism is extremely 
difficult because signs and symptoms can easily be attributed 
optimize results. 
During a lung ventilation scan, the patient inhales a 
to other conditions and symptoms may vary depending on 
the severity of the occurrence. Frequently, a pulmonary 
embolism is confused with a heart attack, pneumonia, 
hyperventilation, congestive heart failure or a panic attack. 
In other cases, there may be no symptoms at all. 
Often, a physician must first eliminate the possibility of 
other lung diseases before determining that the symptoms, if 
any, are caused by a pulmonary embolism. Traditional 
diagnostic methods of testing involve blood tests, chest 
X-rays, and electrocardiograms. These methods are typically 
more effective in ruling out other possible reasons than for 
actually diagnosing a pulmonary embolism. For example, a 40 
chest x-ray may reveal subtle changes in the blood vessel 
patterns after an embolism and signs of pulmonary infarc-
tion. However, chest x-rays often show normal lungs even 
when an embolism is present, and even when the x-rays 
show abnormalities they rarely confirm a pulmonary embo- 45 
lism. Similarly, an electrocardiogram may show 
abnormalities, but it is only useful in establishing the pos-
sibility of a pulmonary embolism. 
gaseous radioactive material. The radioactive material 
becomes distributed throughout the lung's small air sacs, 
known as alveoli, and can be imaged. By comparing this 
scan to the blood supply depicted in the perfusion scan, a 
30 physician may be able to determine whether the person has 
a pulmonary embolism based upon areas that show normal 
ventilation but lack sufficient perfusion. Nevertheless, a 
perfusion scan does not always provide clear evidence that 
a pulmonary embolism is the cause of the problem as it often 
35 yields indeterminate results in as many as 70% of patients. 
As a pulmonary embolism alters the ability of the lungs to 
oxygenate the blood and to remove carbon dioxide from the 50 
blood, one method of diagnosing the condition involves 
taking a specimen of arterial blood and measuring the partial 
pressure of oxygen and carbon dioxide in the arterial blood 
(i.e., an arterial blood gas analysis). Although a pulmonary 
embolism usually causes abnormalities in these 55 
measurements, there is no individual finding or combination 
of findings firm the arterial blood gas analysis that allows 
either a reliable way to exclude or specific way of diagnos-
ing pulmonary embolism. In particular, at least 15-20% of 
patients with a documented pulmonary embolism have nor- 60 
mal oxygen and carbon dioxide contents of the arterial 
blood. Accordingly, the arterial blood analysis cannot reli-
ably include or exclude the diagnosis of a pulmonary 
embolism. 
The blood D-dimer assay is another diagnostic method 65 
that has become available for commercial use. The D-dimer 
protein fragment is formed when fibrin is cleaved by plas-
Pulmonary angiograms are popular means of diagnosing 
a pulmonary embolism, but the procedure poses some risks 
and is more uncomfortable than other tests. During a pul-
monary angiogram, a catheter is threaded into the pulmo-
nary artery so that iodine dye can be injected into the 
bloodstream. The dye flows into the regions of the lung and 
is imaged using x-ray technology, which would indicate a 
pulmonary embolism as a blockage of flow in an artery. 
Pulmonary angiograms are more useful in diagnosing a 
pulmonary embolism than some of the other traditional 
methods, but often present health risks and can be expen-
sive. Although frequently recommended by experts, few 
physicians and patients are willing to undergo such an 
invasive procedure. 
Spiral volumetric computed tomography is another diag-
nostic tool that has recently been proposed as a less invasive 
test which can deliver more accurate results. The proce-
dure's reported sensitivity has varied widely, however, and 
it may only be useful for diagnosing an embolism in central 
pulmonary arteries as it is relatively insensitive to clots in 
more remote regions of the lungs. 
These pulmonary vascular imaging tests have several 
disadvantages in common. Nearly all require ionizing radia-
tion and invasiveness of, at a minimum, an intravenous 
catheter. The imaging tests also typically involve costs of 
more than $1,000 for the patient, take more than two hours 
to perform, and require special expertise such as a trained 
technician to perform the tests and acquire the images and a 
board-certified radiologist to interpret the images. Notably, 
none are completely safe for patients who are pregnant. As 
a result of these shortcomings, the imaging procedures are 
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not available in many outpatient clinic settings and in many 
portions of third world countries. 
Objects and Advantages 
4 
It is a principal object and advantage of the present 
invention to provide physicians with an instrument for 5 
non-invasively diagnosing pulmonary vascular occlusions. 
arteries 12 is reached. The inhaled air 18 is then, as seen in 
FIG. 2, expired as exhaled air 20. Exhaled air 20 from 
properly functioning lungs typically contains a partial pres-
sure of oxygen of about eighty (80) torr and a partial 
pressure of carbon dioxide of about forty ( 40) torr. 
FIG. 3 depicts the functioning of a respiratory system 
afflicted with a pulmonary embolism 22 which, as an 
example, occludes blood flow to an afflicted lung 24. As a 
result, there is a reduction in the number of alveoli 16 that 
It is an additional object and advantage of the present 
invention to provide an instrument that accurately diagnoses 
pulmonary vascular occlusions. 
It is a further object and advantage of the present inven-
tion to provide an instrument for measuring and interpreting 
pulmonary test data. 
Other objects and advantages of the present invention will 
in part be obvious, and in part appear hereinafter. 
SUMMARY OF THE INVENTION 
In accordance with the foregoing objects and advantages, 
the present invention provides a device and method for 
non-invasively diagnosing a pulmonary embolism. The 
device of the present invention comprises a breathing tube 
having sensors for measuring the flow of air into and out of 
10 participate in gas exchange. This volume of space available 
in the alveoli 16 that is lost from participation is commonly 
referred to as alveolar deadspace. Due to the deadspace and 
loss of total alveolar volume available for gas exchange, 
afflicted lung 24 does not exchange gases as readily as the 
15 healthy lung 10. Accordingly, exhaled air 26 contains a 
higher partial pressure of oxygen and lower partial pressure 
of carbon dioxide than air exhaled from a healthy lung. In 
the example depicted in FIG. 3, exhaled air 26 exiting the 
respiratory system contains a partial pressure of oxygen of 
20 about eighty-five (85) torr and a partial pressure of carbon 
dioxide of about twenty (20) torr. Thus, the ratio of carbon 
dioxide to oxygen in exhaled air 26 from afflicted lung 24 
(i.e., 20:85) is smaller than the ratio in exhaled air 20 from 
healthy lung 10 (i.e., 40:80) as seen in FIG. 2. a patient's lungs as well as the amount of oxygen, carbon 
dioxide, or nitrogen. Alternatively, the device can comprise As seen in FIG. 4, a system 28 for measuring and 
diagnosing pulmonary disorders comprises a measuring unit 
30 in combination with a data processing unit 50 and a 
display screen 60. Measuring unit 30 determines the overall 
flow of air inhaled into and exhaled out of the lungs while 
a sensor such as a infrared or mass spectrometer capable of 25 
mastering the quantity of a non-ambient gas which is 
excreted via the lungs after injection into a patient. The 
device further comprises a data processing unit which deter-
mines the concentrations of the expired gases and total 
volume of gas expired for display on a screen. The likeli-
hood that a pulmonary embolism is present can be deter-
mined by comparison of the results to predetermined data 
from normal and afflicted populations. 
30 simultaneously determining the partial pressure of oxygen 
and carbon dioxide. Data processing unit 50 computes the 
concentrations of carbon dioxide, oxygen, and nitrogen from 
the partial pressures and determines the ratio of carbon 
dioxide to oxygen from the raw data obtained by measuring 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is an illustration of a respiratory system during 
inhalation. 
FIG. 2 is an illustration of a respiratory system during 
exhalation. 
FIG. 3 is an illustration of a respiratory system afflicted 
with a pulmonary vascular occlusion during exhalation. 
FIG. 4 is a schematic representation of the system of the 
present invention. 
35 unit 30. The ratio of carbon dioxide to oxygen is then plotted 
against expired volume on display screen 60. By comparing 
the carbon dioxide ratios to average readings, the likelihood 
that a given patient has a pulmonary embolism can be 
determined. 
40 Measuring unit 30 comprises a patient mouthpiece 32 
connected in fluid communication to a breathing tube 34 
having an open end 42 through which air can be inhaled or 
exhaled. Measuring unit 30 further comprises three sensors; 
a pneumotach 36, a capnometer 38, and an oxygen monitor 
FIG. 5 is a perspective view of an attachment to the 45 40. The three sensors are situated in series and in-line with breathing tube 34 for simultaneously measuring the flow, 
carbon dioxide, and oxygen levels of inhaled and exhaled 
air. Infrared and paramagnetic type sensors are preferred 
respectively. Sensors using spectrometric techniques may 
invention. 
FIG. 6 is an illustration of a display screen readout. 
FIG. 7 is a schematic representation of the system of the 
present invention. 
DETAILED DESCRIPTION 
Referring now to the drawing in which like reference 
numerals refer to like parts throughout, there is seen in FIG. 
1 a representation of lungs 10 free from any pulmonary 
occlusions. In healthy lungs 10, blood flows freely from the 
pulmonary arteries 12 into the capillaries 14 surrounding the 
individual alveoli 16 of the lungs 10. When inhaled air 18 is 
drawn into the lungs 10 and alveoli 16, oxygen is transferred 
from the inhaled air 18 to the blood stream and carbon 
dioxide is transferred out. Inhaled air 18 typically contains 
an oxygen partial pressure of approximately one hundred 
(100) torr and a carbon dioxide partial pressure of zero (0) 
torr. 
Once the inhaled air 18 reaches the alveoli 16, the oxygen 
content decreases while the carbon dioxide content increases 
until an equilibrium with blood gas levels in the pulmonary 
50 also work for both oxygen and carbon dioxide measure-
ments providing they can supply data with rapid enough 
response time for breath-to-breath, real-time plotting. The 
mainstream technique for measuring the inhaled or exhaled 
air is preferred, but the sidestream technique may also be 
55 effective. 
As seen in FIG. 5, a T-piece adaptor 70 may optionally be 
provided at open end 42 of breathing tube 34 for use with 
patients that are oxygen dependant. T-piece adapter 70 
contains an inlet valve 72 and an outlet valve 74 which 
60 properly direct the passage of inhaled and exhaled air 
through the breathing tube 34. By connecting an oxygen 
dependant patient's supply to the intake valve 72, inhaled air 
can first be passed through the three sensors 36, 38, 40 to 
establish baseline readings of the oxygen and carbon dioxide 
65 concentrations for comparison to exhaled air, since an 
oxygen dependent patient receives air that has different 
concentrations than present in ambient air. 
US 6,881,193 B2 
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Data processing unit 50 comprises a commercially avail-
able computer processor programmed with software for the 
interpretation of the data obtained from measuring unit 30 
and background comparison data. Software can be specifi-
cally developed to perform the necessary calculations to 5 
determine the partial pressures and carbon dioxide to oxygen 
ratios or software can optionally be purchased commercially 
and, if necessary, modified to run the appropriate algorithms. 
After additional research, the background comparison data 
can be updated based on data obtained from use of the 10 
invention to further refine expected normal values. 
Display screen 60 comprises a cathode ray tube or other 
visual display for displaying computerized data. Screen 60 
can optionally display graphs representing predetermined 
reference or background data for test populations against 15 
which the current readings can be plotted for a visual 
comparison. In addition to displaying the carbon dioxide to 
oxygen ratios as a function of time calculated by data 
processing unit 50, screen 60 may optionally display a plot 
of the expired oxygen and carbon dioxide partial pressures. 20 
Using this display, a physician may estimate the efficiency of 
alveolar ventilation in patients with acute respiratory distress 
syndromes to assist in deciding the mechanical ventilation 
settings. 
In addition to the three primary sensors 36, 38, 40, data 25 
processing unit 50 may optionally be connected to a pulse 
oximeter 44 that measures arterial oxygen saturation of 
hemoglobin in the airterial blood. From this data, and the 
additional measurement of pH and hemoglobin concentra-
tion in a peripheral venous blood sample, the cardiac output 30 
of the patient can be calculated according to the Fick 
equation. In order to perform the Fick equation, the average 
total oxygen consumed, the arterial oxygen content and 
venous oxygen content must be determined. The average 
total oxygen consumed can be determined from the oxygen 35 
tension and flow curves over a predetermined time period. 
For the purposes of determining cardiac output, a one minute 
time period is sufficient. The arterial oxygen content can be 
estimated by multiplying the arterial oxygen saturation 
(measured by pulse oximeter 44) by the hemoglobin con- 40 
centration (determined from the venous blood sample). The 
venous oxygen content can be calculated by determining the 
nadir (mean lowest) oxygen tension measured during expi-
ration over the predetermined time period. From the nadir 
oxygen tension, venous oxygen saturation can be estimated 45 
according to published oxygen binding curves for the mea-
sured pH. The venous oxygen content is then calculated by 
multiplying the venous oxygen saturation by the venous 
hemoglobin (measured from the venous blood sample). 
Once these calculations have been made, the cardiac output 50 
is determined by dividing the total oxygen consumed by the 
difference between the arterial oxygen content and the 
venous oxygen content. The algorithm for the Fick calcu-
lation can be programmed into the data processing unit 
software and the results displayed on screen 60 The cardiac 55 
output measurement is useful for assisting the physician in 
determining the success or failure of treatment designed to 
relieve pulmonary vascular obstructions, or to treat circula-
tory shock. 
Device 28 is used by having a patient breathe (inhale and 60 
exhale a predetermined number of times in succession) 
through mouthpiece 32 of the measuring unit 30. As the 
patient inhales and exhales the pneumotach flow sensor 36, 
capnometer 38, and oxygen monitor 40 perform their 
respective readings, which are then electrically transmitted 65 
via wires or cabling to data processing unit 50. The pro-
grammable software loaded into data processing unit 50 
6 
convert the measurements into volume and concentration 
readings, calculate the carbon dioxide to oxygen ratio, and 
display this ratio on screen 60 in the form of a graph against 
the volume of air expired. Readings may be optimized by 
requiring the patient to hold in inhaled air for several 
heartbeats before exhaling through the mouthpiece 32 of the 
measuring unit 30. It is generally accepted that patients 
without a pulmonary embolism will normally have a carbon 
dioxide to oxygen ratio of 0.30 or greater while patients with 
a pulmonary embolism will have a carbon dioxide to oxygen 
ratio of 0.25 or less. 
Device 28 may also be used for the detection of whole-
body oxygen consumption and determination of the 
adequacy of oxygen delivery during resuscitation from 
shock. During conditions of systemic inflammation the body 
will extract oxygen at higher levels than normal, resulting in 
an increase in the carbon dioxide to oxygen ratio in exhaled 
air. By using T-piece 70 in the manner explained above, the 
concentration of the oxygen provided to the patient and the 
concentration of the oxygen exhaled can be determined. As 
illustrated in FIG. 6, when the level of oxygen delivery (i.e., 
the amount provided minus the amount exhaled) observed at 
two inspired oxygen concentrations reaches normal levels a 
physician has visual confirmation that the resuscitation 
performed is adequate. One method of determining the 
adequacy of resuscitation is to determine oxygen delivery at 
both relatively low fixed concentrations of oxygen and at 
relatively high fixed concentration. Relatively low concen-
trations include from about twenty-one to thirty percent 
(21-30%) oxygen and relatively high oxygen concentrations 
involve about forty-five to fifty percent (45-50%) oxygen. 
The difference between oxygen delivery at relatively low 
concentrations verses relatively high concentrations can be 
compared against a nomogram for healthy patients of similar 
age, body mass, body mass index, and gender and used to 
assess the adequacy of fluid and vasopressor resuscitation. 
Data processing unit 50 can additionally be programmed 
to display on screen 60 any of the individual measurements 
taken by sensors 36, 38, 40, and 44, or combinations thereof 
for diagnostic purposes. For example, a plot of the expired 
carbon dioxide and oxygen concentration over time could be 
used to estimate the efficiency of alveolar ventilation in 
patients with acute respiratory distress syndrome. 
Additionally, the plotted data from sensors 36, 38, 40, and 44 
could be used to assist in deciding how to properly adjust 
mechanical ventilators setting, such as the degree of positive 
end-expiratory pressure, minute ventilation, and peak 
inspiratory pressure settings, to optimize patient care. For 
example, data from sensors 36, 37, 40, and 44, can be plotted 
individually in patients who are being mechanically venti-
lated. By simultaneously plotting the partial pressures of 
oxygen and carbon dioxide as a function of volume of each 
breath, the amount of carbon dioxide released and percent-
age of oxygen extracted can be determined. If the barometric 
pressure is known or inputted into data processing unit 50, 
the efficiency of alveolar ventilation during each tidal vol-
ume breath can be calculated. This information can then be 
used to adjust mechanical ventilation to optimize alveolar 
efficiency or breathing alveolar ventilation efficiency. 
Measuring unit 30 may comprise a pneumotach 36 and an 
infrared spectrometer 80 in fluid communication with 
breathing tube 34. Spectrometer 80 is capable of measuring 
the expired concentration of other substances, such as gases 
not normally present in ambient air, which are eliminated or 
excreted from a patient via the lungs. The patient is injected 
intravenously with a predetermined safe quantity of the 
substance and allowed to exhale through measuring unit 30 
US 6,881,193 B2 
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for approximately five minutes. During this time period, the 
measurements from pneumotach 36 and spectrometer 80 are 
provided to data processing unit 50 which computes the 
concentration of the substance (as either a percentage or 
partial pressure) and provides the results for display on 5 
screen 60. As with the previous embodiments of the present 
invention, the presence or absence of a pulmonary embolism 
can be determined based upon a comparison of the particular 
patient's displayed results to elimination curves derived 
from a large sampling of normal and affected populations. A 10 
mass spectrometer in fluid communication with measuring 
unit 30 could alternatively be used to measure the quantity 
8 
What is claimed is: 
1. A device for non-invasively diagnosing abnormal res-
piratory function, comprising: 
means for detecting the amount of a non-ambient gas 
exhaled by a patient; 
means for calculating the concentration of said gas; and 
means for plotting said concentration of said gas as a 
function of expired volume against corresponding data 
from normal and afflicted populations. 
2. The device of claim 1, wherein said means for detecting 
the amount of a non-ambient gas exhaled by a patient 
comprises a spectrometer. 
of inert gas expired by the patient. 
One substance which is medically safe for use in humans 
3. The device of claim 2, wherein said means for calcu-
15 lating the concentration of said gas comprises a data pro-
cessor connected to said spectrometer. is sulfur hexafloride. For example, a useful preparation of 
sulfur hexafloride is Sano Vue®, a suspension of stabilized 
sulfur hexafloride microbubbles in a 0.9% saline solution 
produced by Bracco SpA, Milan, Italy. The patient is 
injected via a "butterfly" needle with 0.03 ml/kg of the sulfur 
hexafloride preparation, thus avoiding the need for an intra-
venous catheter. Infrared spectrometer 80 measures the 
concentration of sulfur hexafloride (as either a percent or 
partial pressure) and provides the data 82 to data processing 
unit 50. The moles of expired sulfur hexafloride are then 25 
calculated and plotted on screen 60 as a function of expired 
volume along. Screen 60 can also display data from normal 
and afflicted populations for diagnostic purposes. Other 
substances which can be prepared in solution and used in 
this manner are acetylene, ethane, cyclopropane, halothane, 30 
ether, and acetone. 
4. The device of claim 3, wherein said means for plotting 
said concentration of said gas as a function of expired 
volume against corresponding data from normal and 
20 
afflicted populations comprises a display screen intercon-
nected to said data processor. 
While measuring unit 30 optimally includes capnometer 
38 for measuring expired carbon dioxide concentration and 
oxygen monitor 40 for measuring expired oxygen 
concentrations, either capnometer 38 or oxygen monitor 40 35 
may be replaced by a mass spectrometer which can measure 
expired nitrogen and provide the data to data processing unit 
50 for calculation of concentration As ambient air is prima-
rily comprised of three gases, i.e., nitrogen, oxygen, and 
carbon dioxide, measurement of the concentration of any 40 
two gases will allow an approximate determination of the 
third using standard tables or calculations. Thus, the mass 
spectrometer can replace either capnometer 38 or oxygen 
monitor 40 and data processing unit 50 can be programmed 
with the necessary calculations to determine the oxygen and 45 
carbon dioxide concentrations needed for diagnosis. 
5. A method for diagnosing abnormal respiratory function, 
comprising the steps of: 
injecting a patient with a predetermined amount of a 
non-ambient gas in a sterile solution; 
providing a mouthpiece to said patient; 
allowing said patient to exhale through said mouthpiece; 
measuring the exhaled concentration of said gas over a 
predetermined time period; 
displaying a graph of the moles of said gas expired verses 
as a function of the total volume of gases expired; and 
comparing said graph to corresponding data from normal 
and afflicted populations. 
6. The method of claim 5, wherein said non-ambient gas 
is selected from the group consisting of sulfur hexafluoride, 
acetylene, ethane, cyclopropane, halothane, ether, and 
acetone. 
7. The method of claim 5, wherein said non-ambient gas 
in a sterile solution comprises sulfur hexafluoride in about a 
0.9 percent saline solution. 
8. The method of claim 7, wherein said predetermined 
amount comprises about 0.03 ml/kg of sulfur hexafluoride. 
9. The method of claim 8, wherein said patient is injected 
via a butterfly needle. 
* * * * * 
